--Google Plans Anthropic Investment of Up to $40 Billion, Bloomberg Reports-September 2024-www.financetom.com

--Google Plans Anthropic Investment of Up to $40 Billion, Bloomberg Reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Google Plans Anthropic Investment of Up to $40 Billion, Bloomberg Reports

Apr 24, 2026 9:21 AM

11:55 AM EDT, 04/24/2026 (MT Newswires) --

Price: 341.32, Change: +3.57, Percent Change: +1.06

Previous page： --Google Plans Anthropic Investment of Up to $40 Billion, Bloomberg Reports Next page： Wayfair Poised for 'Strong' Q1 Results, Middle East Uncertainty Likely To Remain Overhang, RBC Says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Google Plans Anthropic Investment of Up to $40 Billion, Bloomberg Reports

Apr 24, 2026

11:55 AM EDT, 04/24/2026 (MT Newswires) -- Price: 341.32, Change: +3.57, Percent Change: +1.06 ...

Wayfair Poised for 'Strong' Q1 Results, Middle East Uncertainty Likely To Remain Overhang, RBC Says

Apr 24, 2026

11:54 AM EDT, 04/24/2026 (MT Newswires) -- Wayfair ( W ) is expected to show strong Q1 results, when the company reports its quarterly earnings on Thursday, while the ongoing Iran war remains an overhang on the company's stock, RBC Capital Markets said in a Friday note. RBC maintained its Q1 net sales growth estimate of 5.7%, in-line with consensus,...

Lockheed Martin Faces Higher Risk to Meeting 2026 Outlook, BofA Securities Says

Apr 24, 2026

11:35 AM EDT, 04/24/2026 (MT Newswires) -- Lockheed Martin ( LMT ) is facing increased risk to meeting its outlook for 2026, with the burden of proof falling to H2 after fiscal Q1 earnings and sales came in below estimates, BofA Securities said in a note Friday. The investment firm said cash is the most at risk, with classified programs...

Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says

Apr 24, 2026

11:54 AM EDT, 04/24/2026 (MT Newswires) -- Damora Therapeutics ( DMRA ) is capitalizing on growing validation of using mutant calreticulin targeting therapies in myeloproliferative neoplasms, and may have the additional advantage of a charted regulatory path as a fast-follower over Incyte's ( INCY ) mid-stage candidate, RBC Capital said in a note emailed Friday. RBC said data from Incyte's...